Deep inside a spoonful of ordinary soil, a microscopic chemist has been quietly manufacturing a molecule that could one day help the world’s more than half a billion people with diabetes blunt their deadliest daily adversary: the post-meal blood sugar spike. Researchers report the discovery and characterization of acremopyrone A, a previously unknown α-pyrone derivative isolated from the soil-dwelling fungus Acremonium persicinum, strain 3.2858. In laboratory assays, the compound showed significant inhibitory activity against α-glucosidase, the carbohydrate-cleaving enzyme whose overzealous performance drives sharp glucose surges after meals. Writing in The Journal of Antibiotics, the team describes how they pinned down the molecule’s structure using nuclear magnetic resonance spectroscopy and high-resolution electrospray ionization mass spectrometry, then deployed enzyme kinetics and molecular docking to reveal exactly how the compound interferes with its enzyme target. The finding injects a genuinely new chemical scaffold into the accelerating global search for next-generation, nature-inspired antidiabetic agents.
To understand why a molecule from a fungus matters for metabolic disease, it helps to trace what happens in the gut after a plate of pasta. Starches and complex sugars are far too large to cross the intestinal wall, so before glucose can enter the bloodstream, a cascade of digestive enzymes must dismantle carbohydrates into absorbable single sugars. The final, decisive cut belongs to α-glucosidase, an enzyme anchored in the brush border of the small intestine that snips disaccharides and oligosaccharides into free glucose. When this enzyme works at full efficiency, glucose floods the circulation faster than insulin can manage it, producing the steep postprandial spikes that, repeated thousands of times over the years, damage blood vessels, nerves and organs. Clinical medicine has long exploited this vulnerability. Drugs such as acarbose, miglitol and voglibose slow carbohydrate digestion by inhibiting α-glucosidase, flattening glucose curves after meals and easing the burden on failing insulin signaling. Yet these agents routinely cause gastrointestinal side effects—bloating, flatulence and diarrhea—because undigested carbohydrates ferment in the lower gut, and that discomfort drives many patients to abandon therapy. The hunt for inhibitors built on new structural frameworks, operating through different binding modes and potentially better tolerated, remains genuinely intense.
Nature, and fungi in particular, remain the richest repository of such structures. Microbes synthesize thousands of small molecules known as secondary metabolites—chemical weapons and signaling compounds that are not essential for basic survival but confer decisive advantages in the brutal competition for resources in soil. This subterranean arms race has already given modern medicine some of its most transformative drugs: penicillin from a mold, the cholesterol-lowering statin lovastatin from Aspergillus, and the immunosuppressant cyclosporine from a soil-borne fungus. The genus Acremonium, which famously yielded cephalosporin C, the ancestor of an entire class of antibiotics, has an illustrious pedigree in this arena and continues to produce structurally diverse metabolites with antibiotic, antifungal and enzyme-inhibiting properties. Yet the vast majority of fungal species have never been cultivated in a laboratory, and even well-studied strains harbor silent biosynthetic gene clusters that can, under the right conditions, be coaxed into producing novel chemistry. Every gram of soil, in other words, is an unopened library of potential drugs, and Acremonium persicinum has now contributed a new volume to the collection.
The path from dirt to molecule followed the classic playbook of natural products research, executed with modern analytical firepower. The team isolated Acremonium persicinum strain 3.2858 from a soil sample and grew it under controlled laboratory conditions, allowing the organism to accumulate its arsenal of secondary metabolites in the culture. Fungi invest metabolic energy in these compounds because, in nature, they serve as antibiotics against bacterial rivals, deterrents against grazing animals, or chemical signals exchanged with the environment—roles that intersect, sometimes dramatically, with human pharmacology. The resulting fungal extract was then fractionated, separated into progressively simpler mixtures using chromatographic techniques that sort molecules according to their chemical properties, while each fraction was monitored for biological activity. This bioassay-guided workflow operates like a sieve, letting chemists concentrate their attention on the fractions that actually do something interesting and discard the inert rest. In this case, the search converged on a single, discrete compound that proved to be new to science: an α-pyrone derivative the researchers christened acremopyrone A, designated compound 1 in the study.
Assigning a precise structure to a brand-new natural product is a forensic exercise in molecular interrogation, and the team approached it with the two techniques that define modern structure elucidation. First came high-resolution electrospray ionization mass spectrometry, or HRESIMS, a soft-ionization method that transfers the intact molecule into the gas phase as a charged ion and measures its mass-to-charge ratio with such precision that the exact elemental formula can be calculated from the minuscule deviations introduced by individual isotopes. With the molecular formula secured, attention shifted to nuclear magnetic resonance spectroscopy, which exploits the magnetic behavior of hydrogen and carbon nuclei to map how the atoms in the molecule connect to one another. The two methods act as complementary witnesses: mass spectrometry establishes what the molecule is made of, while NMR testifies to how those atoms are arranged. By interpreting a comprehensive panel of NMR experiments—the kind of correlations that reveal which protons attach to which carbons, which neighboring nuclei communicate through bonds, and which atoms sit close together in space—the researchers assembled the carbon framework piece by piece. The picture that emerged was a six-membered α-pyrone ring, an oxygen-containing heterocycle bearing a distinctive arrangement of substituents that no database had previously recorded, defining acremopyrone A as a genuinely novel structure.
Structure, however, would be a mere curiosity without function. When acremopyrone A was tested against α-glucosidase in vitro, the compound proved to be a significant inhibitor of the enzyme, measurably slowing the breakdown of carbohydrate substrates under assay conditions. The result carries weight for two reasons. First, α-glucosidase inhibition is a pharmacologically crowded field, and genuinely new scaffolds—structural frameworks not shared with established inhibitors such as the sugar-mimicking acarbose—are prized currency for medicinal chemists seeking molecules that bind more selectively or spare patients the digestive side effects of current therapy. Compared with the bulky, carbohydrate-like architectures of existing drugs, a compact microbial α-pyrone offers a radically different starting geometry for drug design. Second, α-pyrones as a chemical class are emerging as remarkably versatile pharmacophores, appearing in natural products with antibacterial, antifungal, anti-inflammatory and antidiabetic activities, which suggests that this core deserves systematic optimization rather than dismissal as a one-off observation.
The most revealing insight came from enzyme kinetic analysis, the experimental discipline used to deduce not merely whether a molecule inhibits an enzyme, but exactly how. By measuring reaction velocities across a grid of substrate and inhibitor concentrations, the team dissected acremopyrone A’s mechanism of action and identified a mixed-type pattern of inhibition. In kinetic terms, mixed-type inhibition means the inhibitor can bind both the free enzyme and the enzyme–substrate complex, typically with different affinities for the two states. The consequences show up unmistakably in classical diagnostic plots: as inhibitor concentration rises, the lines of a Lineweaver–Burk analysis fail to converge on a single point, and both the apparent Km—a readout of how efficiently the enzyme captures its substrate—and the Vmax, the maximum achievable reaction velocity, shift simultaneously. Mechanistically, this signature indicates that acremopyrone A does not simply occupy the catalytic site and elbow aside incoming sugar substrate, the way purely competitive inhibitors do. Instead, it appears to recognize features at or beyond the catalytic center, binding in a manner that compromises the enzyme’s architecture whether or not substrate is already in place. That behavior points toward binding regions overlapping or adjacent to the active site—territory that purely competitive drugs never touch, and that offers medicinal chemists an alternative surface to target.
To visualize where the molecule actually settles on its target, the researchers turned to molecular docking, a computational technique that predicts how a small molecule fits into the three-dimensional structure of a protein. Docking algorithms generate large ensembles of candidate binding poses and score each one by predicted interaction energy; the top-ranked conformations are then inspected for the specific contacts—hydrogen bonds, hydrophobic packing, electrostatic attractions—that would stabilize the complex in real life. The docking studies placed acremopyrone A in a binding arrangement consistent with the mixed-type mechanism inferred from kinetics, pointing to stabilizing contacts that support genuine affinity for the enzyme. Such agreement between laboratory measurement and computational modeling does more than confirm a result; it hands medicinal chemists a structural hypothesis. If the compound’s contacts with the enzyme can be mapped with confidence, analogs can be rationally designed to strengthen those interactions, sharpen selectivity for α-glucosidase over related digestive enzymes, and begin the iterative sculpting that transforms a screening hit into a credible drug candidate.
For now, acremopyrone A is a promising lead, not a medicine. The distance between an in vitro enzyme assay and a clinical antidiabetic agent is measured in years of medicinal chemistry, pharmacokinetic profiling, toxicity testing and, eventually, studies in animal models and humans. But the discovery arrives at a consequential moment. Diabetes affects more than half a billion adults worldwide and the count continues to climb; existing α-glucosidase inhibitors impose tolerability burdens that push many patients off treatment; and the pharmaceutical pipeline is hungry for natural scaffolds with unexploited binding modes. Acremopyrone A offers exactly that combination: a structurally novel α-pyrone, confirmed significant inhibitory activity against its enzyme target, and a defined kinetic mechanism that tells chemists precisely where to aim their optimization efforts. It is also a reminder that some of the most forward-looking drug discovery still begins with the oldest of methods—growing a fungus from a pinch of soil and asking what it can do. As researchers continue to mine the planet’s microbial dark matter, molecules like acremopyrone A suggest that the next generation of glucose-taming drugs may be waiting underground right now, synthesized by organisms too small to see and too chemically inventive to ignore.
Subject of Research: Discovery of acremopyrone A, a new α-pyrone derivative from the soil-derived fungus Acremonium persicinum 3.2858, and its significant inhibitory activity against α-glucosidase
Subject of Research: Medicine
Article Title: Discovery of new α-pyrone derivative with α-glucosidase inhibitory activity from the fungus Acremonium persicinum
Article References: Tu, Y., Zhang, B., Bao, M., Ji, M., & Liu, L. (2026). Discovery of new α-pyrone derivative with α-glucosidase inhibitory activity from the fungus Acremonium persicinum. The Journal of Antibiotics. https://doi.org/10.1038/s41429-026-00946-8
Image Credits: AI Generated
DOI: 10.1038/s41429-026-00946-8
Keywords: Acremonium persicinum, acremopyrone A, α-pyrone, α-glucosidase inhibition, natural products, soil-derived fungus, secondary metabolites, enzyme kinetics, mixed-type inhibition, molecular docking, type 2 diabetes, drug discovery
Cite Scienmag News
APA MLA Chicago
Roger Howard. (August 30, 2026). New α-pyrone derivative from fungus Acremonium persicinum inhibits α-glucosidase. Scienmag. https://scienmag.com/new-%ce%b1-pyrone-derivative-from-fungus-acremonium-persicinum-inhibits-%ce%b1-glucosidase/
Roger Howard. “New α-pyrone derivative from fungus Acremonium persicinum inhibits α-glucosidase.” Scienmag, 30 August 2026, https://scienmag.com/new-%ce%b1-pyrone-derivative-from-fungus-acremonium-persicinum-inhibits-%ce%b1-glucosidase/. Accessed 30 August 2026.
Roger Howard. “New α-pyrone derivative from fungus Acremonium persicinum inhibits α-glucosidase.” Scienmag. August 30, 2026. https://scienmag.com/new-%ce%b1-pyrone-derivative-from-fungus-acremonium-persicinum-inhibits-%ce%b1-glucosidase/
Copy citation Download RIS
Tags: Acremonium persicinum natural productacremopyrone Aantidiabetic drug discoverydiscovery of new chemical scaffoldsenzyme kinetics in diabetes treatmentenzyme kinetics in drug developmentfungal bioactive compoundsfungus-derived α-pyrone compoundmarine and soil microorganism drug discoverymolecular docking of enzyme inhibitorsnatural antidiabetic agentsnatural inhibitors for blood sugar controlnext-generation diabetes therapeuticsnovel chemical scaffolds for diabetes treatmentplant-based carbohydrate digestionpost-meal blood sugar managementsoil fungi bioactive metabolitessoil-derived fungi metabolitesstructure elucidation of bioactive moleculesstructure elucidation using NMR and MSα-glucosidase enzyme inhibitionα-glucosidase inhibitionα-pyrone derivative
